TY - JOUR
T1 - Acquired factor XIII deficiency in adult patients during ECMO
T2 - a prospective observational study
AU - Noitz, Matthias
AU - Jenner, Dennis
AU - Tschoellitsch, Thomas
AU - Brooks, Roxane
AU - Erblich, Romana
AU - Krenner, Niklas
AU - Tomić-Mahečić, Tina
AU - Dünser, Martin W
AU - Zierer, Andreas
AU - Meier, Jens
N1 - © 2025. The Author(s).
PY - 2025/11/7
Y1 - 2025/11/7
N2 - Data on factor XIII (FXIII) activity in patients on extracorporeal membrane oxygenation (ECMO) are scarce. In this prospective, observational, single-centre study, we determined the rate of acquired FXIII deficiency in 44 adults during ECMO. We evaluated the relationship between minimum FXIII activity, haemoglobin levels, transfusion requirements, as well as the occurrence of major bleeding events. Descriptive statistical methods, bivariate correlation and receiver operating characteristic curve analyses were applied. Acquired FXIII deficiency (FXIII activity < 70%) was found in 41/44 patients [93.2% (95% CI 85.7-100%)] during ECMO. The minimum FXIII activity was correlated with minimum haemoglobin levels (Spearman-rho, 0.331, 95% CI 0.02-0.57, p = 0.03), packed red blood cell transfusion requirements (Spearman-rho, - 0.32, 95% CI - 0.58 to 0.00, p = 0.03), but not the occurrence of major bleeding events (p = 0.32, Hodges-Lehmann difference - 4.0%, 95% CI - 15.0 to 5.0%) during ECMO. The area under the receiver operating characteristic curve for minimum FXIII activity to predict the occurrence of major bleeding events during ECMO was 0.602 (95% CI 0.375-0.828). The lowest FXIII activity to predict a major bleeding event was 51.0% and 55.5% (Youden index for both, 0.27), respectively. In conclusion, acquired FXIII deficiency is highly frequent in adult ECMO patients. Lower FXIII activity showed modest correlations with nadir haemoglobin and pRBC exposure, but did not discriminate patients with major bleeding. Larger studies are needed to determine whether routine FXIII monitoring and targeted replacement improve outcomes during ECMO.
AB - Data on factor XIII (FXIII) activity in patients on extracorporeal membrane oxygenation (ECMO) are scarce. In this prospective, observational, single-centre study, we determined the rate of acquired FXIII deficiency in 44 adults during ECMO. We evaluated the relationship between minimum FXIII activity, haemoglobin levels, transfusion requirements, as well as the occurrence of major bleeding events. Descriptive statistical methods, bivariate correlation and receiver operating characteristic curve analyses were applied. Acquired FXIII deficiency (FXIII activity < 70%) was found in 41/44 patients [93.2% (95% CI 85.7-100%)] during ECMO. The minimum FXIII activity was correlated with minimum haemoglobin levels (Spearman-rho, 0.331, 95% CI 0.02-0.57, p = 0.03), packed red blood cell transfusion requirements (Spearman-rho, - 0.32, 95% CI - 0.58 to 0.00, p = 0.03), but not the occurrence of major bleeding events (p = 0.32, Hodges-Lehmann difference - 4.0%, 95% CI - 15.0 to 5.0%) during ECMO. The area under the receiver operating characteristic curve for minimum FXIII activity to predict the occurrence of major bleeding events during ECMO was 0.602 (95% CI 0.375-0.828). The lowest FXIII activity to predict a major bleeding event was 51.0% and 55.5% (Youden index for both, 0.27), respectively. In conclusion, acquired FXIII deficiency is highly frequent in adult ECMO patients. Lower FXIII activity showed modest correlations with nadir haemoglobin and pRBC exposure, but did not discriminate patients with major bleeding. Larger studies are needed to determine whether routine FXIII monitoring and targeted replacement improve outcomes during ECMO.
KW - Humans
KW - Female
KW - Male
KW - Extracorporeal Membrane Oxygenation/adverse effects
KW - Factor XIII Deficiency/etiology
KW - Middle Aged
KW - Adult
KW - Prospective Studies
KW - Hemorrhage/etiology
KW - Factor XIII/metabolism
KW - Aged
KW - ROC Curve
KW - Hemoglobins/metabolism
UR - https://www.scopus.com/pages/publications/105021067993
U2 - 10.1038/s41598-025-26452-9
DO - 10.1038/s41598-025-26452-9
M3 - Article
C2 - 41203730
SN - 2045-2322
VL - 15
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 39110
ER -